1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine has been researched along with Dyskinesia, Drug-Induced in 128 studies
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine: A dopaminergic neurotoxic compound which produces irreversible clinical, chemical, and pathological alterations that mimic those found in Parkinson disease.
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine : A tetrahydropyridine that is 1,2,3,6-tetrahydropyridine substituted by a methyl group at position 1 and a phenyl group at position 4.
Dyskinesia, Drug-Induced: Abnormal movements, including HYPERKINESIS; HYPOKINESIA; TREMOR; and DYSTONIA, associated with the use of certain medications or drugs. Muscles of the face, trunk, neck, and extremities are most commonly affected. Tardive dyskinesia refers to abnormal hyperkinetic movements of the muscles of the face, tongue, and neck associated with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS). (Adams et al., Principles of Neurology, 6th ed, p1199)
| Excerpt | Relevance | Reference |
|---|---|---|
| "As an index of terminal serotonin innervation density, we measured radioligand binding to the plasma membrane serotonin transporter (SERT) in levodopa-treated dyskinetic and nondyskinetic subjects, using brain tissue from both rat and monkey models of Parkinson disease as well as parkinsonian patients." | 3.76 | Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia. ( Bezard, E; Cenci, MA; Descarries, L; Dovero, S; Lees, AJ; O'Sullivan, SS; Parent, M; Rylander, D, 2010) |
| " During long-term levodopa therapy, patients develop abnormal movements, dyskinesias, the pathophysiological basis of which is poorly understood." | 3.70 | Internal globus pallidus discharge is nearly suppressed during levodopa-induced dyskinesias. ( Desimone, R; Fiorani, M; Oldfield, EH; Papa, SM, 1999) |
| "Models of Parkinson's disease (PD) can be produced in several non-human primate (NHP) species by applying neurotoxic lesions to the nigrostriatal dopamine pathway." | 2.52 | Symptomatic Models of Parkinson's Disease and L-DOPA-Induced Dyskinesia in Non-human Primates. ( Fox, SH; Johnston, TM, 2015) |
| "One major goal of current research in Parkinson's disease (PD) is the discovery of novel agents to improve symptomatic management." | 2.42 | Recent failures of new potential symptomatic treatments for Parkinson's disease: causes and solutions. ( Linazasoro, G, 2004) |
| " Regular dosing with levodopa or apomorphine reliably resulted in peak dose dyskinesia." | 2.38 | The use of thalamotomy in the treatment of levodopa-induced dyskinesia. ( Page, RD, 1992) |
| "This reduction of parkinsonism was not accompanied by an exacerbation of dyskinesia or PLBs." | 1.56 | Monoamine oxidase A inhibition with moclobemide enhances the anti-parkinsonian effect of L-DOPA in the MPTP-lesioned marmoset. ( Bédard, D; Frouni, I; Gourdon, JC; Hamadjida, A; Huot, P; Kwan, C; Nuara, SG, 2020) |
| "Six common marmosets developed parkinsonism following administration of MPTP, after which they were treated chronically with L-DOPA to induce stable dyskinesia and PLBs." | 1.48 | Nefazodone reduces dyskinesia, but not psychosis-like behaviours, in the parkinsonian marmoset. ( Bédard, D; Frouni, I; Gourdon, JC; Hamadjida, A; Huot, P; Kwan, C; Nuara, SG, 2018) |
| "Levodopa treatment increased the specific binding of NMDA receptors in the basal ganglia." | 1.42 | Changes in glutamate receptors in dyskinetic parkinsonian monkeys after unilateral subthalamotomy. ( Di Paolo, T; Grégoire, L; Jourdain, VA; Morin, N; Morissette, M, 2015) |
| " This effort led to the discovery of 1-methyl-3-(4-methylpyridin-3-yl)-6-(pyridin-2-ylmethoxy)-1H-pyrazolo[3,4-b]pyrazine (PF470, 14) as a highly potent, selective, and orally bioavailable mGluR5 NAM." | 1.40 | Discovery and preclinical characterization of 1-methyl-3-(4-methylpyridin-3-yl)-6-(pyridin-2-ylmethoxy)-1H-pyrazolo-[3,4-b]pyrazine (PF470): a highly potent, selective, and efficacious metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulat ( Balan, G; Barreiro, G; Boscoe, BP; Chen, L; Chenard, LK; Cianfrogna, J; Claffey, MM; Coffman, KJ; Drozda, SE; Dunetz, JR; Fonseca, KR; Galatsis, P; Grimwood, S; Lazzaro, JT; Mancuso, JY; Miller, EL; Reese, MR; Rogers, BN; Sakurada, I; Shaffer, CL; Skaddan, M; Smith, DL; Stepan, AF; Trapa, P; Tuttle, JB; Verhoest, PR; Walker, DP; Wright, AS; Zaleska, MM; Zasadny, K; Zhang, L, 2014) |
| "In animal models of Parkinson's disease (PD), the serotonergic (5-hydroxytryptamine, 5-HT) system is thought to play an important pathophysiological role in the development and expression of l-3,4-dihydroxyphenylalanine (l-3,4-dihydroxyphenylalanine-DOPA)-induced dyskinesia (LID)." | 1.40 | Effects of L-tryptophan on L-DOPA-induced dyskinesia in the L-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque model of Parkinson's disease. ( Bezard, E; Ko, WK; Li, Q, 2014) |
| "L-DOPA-induced dyskinesias (LID)s are abnormal involuntary movements limiting the chronic use of L-DOPA, the main pharmacological treatment of Parkinson's disease (PD)." | 1.39 | Basal ganglia serotonin 1B receptors in parkinsonian monkeys with L-DOPA-induced dyskinesia. ( Di Paolo, T; Morissette, M; Parent, M; Riahi, G; Samadi, P, 2013) |
| " We retrospectively analyzed data from 17 stable HP rhesus monkeys treated long-term with chronic intermittent dosing of levodopa (LD) in an attempt to induce choreoathetoid and dystonic dyskinesias." | 1.37 | Dyskinesias do not develop after chronic intermittent levodopa therapy in clinically hemiparkinsonian rhesus monkeys. ( Bakay, RA; Deogaonkar, M; Lieu, CA; Subramanian, T, 2011) |
| "Levodopa-induced dyskinesias (LIDs) are abnormal involuntary movements induced by the chronic use of levodopa (l-Dopa) limiting the quality of life of Parkinson's disease (PD) patients." | 1.37 | Brain 5-HT(2A) receptors in MPTP monkeys and levodopa-induced dyskinesias. ( Di Paolo, T; Morissette, M; Parent, M; Riahi, G, 2011) |
| " Furthermore, chronic administration of low doses of the 5-HT(1) agonists in combination was able to prevent development of dyskinesia, and reduce the up-regulation of FosB after daily treatment with l-DOPA in the rat 6-OHDA model." | 1.35 | Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. ( Bezard, E; Björklund, A; Carlsson, T; Carta, M; Di Luca, M; Gardoni, F; Kirik, D; Li, Q; Marcello, E; Muñoz, A; Qin, C, 2008) |
| "Ropinirole treatment was continued but some animals also received l-dopa BID or four times daily (QID) with and without entacapone or vehicle for a further 16 days." | 1.34 | The administration of entacapone prevents L-dopa-induced dyskinesia when added to dopamine agonist therapy in MPTP-treated primates. ( Jackson, MJ; Jenner, P; Olanow, W; Rose, S; Smith, LA; Stockwell, KA; Tayarani-Binazir, K; Zubair, M, 2007) |
| "Nicotine pretreatment reduced peak and total levodopa-induced dyskinesias in levodopa-naive monkeys over an 8-week period, with a decrease in total dyskinesias of about 50%." | 1.34 | Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys. ( Cox, H; Di Monte, D; Langston, JW; O'Leary, K; Parameswaran, N; Quik, M, 2007) |
| " These data support the notion that pulsatile stimulation contributes to the development of dyskinesia and suggests that more frequent dosing of L-dopa plus entacapone may be a useful treatment strategy for patients in the early stages of Parkinson's disease." | 1.33 | Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates. ( Al-Barghouthy, G; Jackson, MJ; Jenner, P; Kuoppamaki, M; Olanow, W; Rose, S; Smith, LA, 2005) |
| "Long-term treatment of Parkinson's disease with levodopa is compromised by the development of motor complications, including on-off fluctuations and involuntary movements termed dyskinesia." | 1.32 | Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson's disease. ( Brotchie, JM; Crossman, AR; Duty, S; Fox, SH; Henry, B, 2003) |
| " Mild and advanced parkinsonism in nonhuman primates can be produced with fixed dosing regimens of MPTP." | 1.31 | D(1) dopamine receptor agonists are more effective in alleviating advanced than mild parkinsonism in 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-treated monkeys. ( Goulet, M; Madras, BK, 2000) |
| " Selective adenosine A(2A) receptor antagonists, such as KW-6002, may be one means of reducing the dosage of L-DOPA used in treating Parkinson's disease and are potentially a novel approach to treating the illness both as monotherapy and in combination with dopaminergic drugs." | 1.31 | Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys. ( Jackson, MJ; Jenner, P; Kanda, T; Kase, H; Kuwana, Y; Nakamura, J; Pearce, RK; Smith, LA, 2000) |
| " We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0." | 1.30 | Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929: an acute study in parkinsonian levodopa-primed monkeys. ( Bédard, PJ; Britton, DR; Grondin, R; Shiosaki, K, 1997) |
| " These results are consistent with previous work highlighting the importance of aberrant amine production in neurological disease and demonstrate that treatments that reduce endogenous melatonin bioavailability can ameliorate experimental PD." | 1.30 | A therapeutic role for melatonin antagonism in experimental models of Parkinson's disease. ( Armstrong, SM; Willis, GL, 1999) |
| "Baclofen was also useful in one monkey against a more dystonic form of dyskinesia." | 1.29 | Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys. ( Bédard, PJ; Gomez-Mancilla, B, 1993) |
| " Long-term use of madopa developed a peak-dose dyskinesia of the face and the limbs contralateral to the MPTP-treated side." | 1.28 | [Dopa-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated hemiparkinsonian monkeys]. ( Chen, S, 1992) |
| "Choreic movements were always most prevalent at the time of peak effect, whereas dystonia was apparent at the time of peak effect and at "end-of-dose", and was occasionally observed spontaneously." | 1.28 | Characterisation of dyskinesias induced by L-dopa in MPTP-treated squirrel monkeys. ( Boyce, S; Iversen, SD; Rupniak, NM; Steventon, MJ, 1990) |
| " The dose-response curve for NB-355 was shifted to the right such that approximately twice the dopa equivalent dose of NB-355 was required to stimulate locomotor activity to the same level observed for L-DOPA." | 1.28 | NB-355: a novel prodrug for L-DOPA with reduced risk for peak-dose dyskinesias in MPTP-treated squirrel monkeys. ( Iversen, SD; Miyaji, M; Naruse, T; Rupniak, NM; Tye, SJ, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (7.03) | 18.7374 |
| 1990's | 32 (25.00) | 18.2507 |
| 2000's | 59 (46.09) | 29.6817 |
| 2010's | 21 (16.41) | 24.3611 |
| 2020's | 7 (5.47) | 2.80 |
| Authors | Studies |
|---|---|
| Nuara, SG | 3 |
| Gourdon, JC | 3 |
| Maddaford, S | 1 |
| Huot, P | 4 |
| Morissette, M | 10 |
| Bourque, M | 4 |
| Tremblay, MÈ | 1 |
| Di Paolo, T | 18 |
| Grégoire, L | 12 |
| Patel, W | 3 |
| Dickens, D | 3 |
| Snodgrass, R | 3 |
| Moreau, C | 1 |
| Rolland, AS | 1 |
| Pioli, E | 1 |
| Li, Q | 6 |
| Odou, P | 1 |
| Barthelemy, C | 1 |
| Lannoy, D | 1 |
| Demailly, A | 1 |
| Carta, N | 1 |
| Deramecourt, V | 1 |
| Auger, F | 1 |
| Kuchcinski, G | 1 |
| Laloux, C | 1 |
| Defebvre, L | 1 |
| Bordet, R | 1 |
| Duce, J | 1 |
| Devedjian, JC | 1 |
| Bezard, E | 11 |
| Fisichella, M | 1 |
| Devos, D | 1 |
| Mann, E | 1 |
| Jackson, M | 4 |
| Lincoln, L | 1 |
| Fisher, R | 1 |
| Rose, S | 6 |
| Duty, S | 2 |
| Hamadjida, A | 2 |
| Kwan, C | 2 |
| Frouni, I | 2 |
| Bédard, D | 2 |
| Beaudry, F | 1 |
| Ahn, S | 1 |
| Song, TJ | 1 |
| Park, SU | 1 |
| Jeon, S | 1 |
| Kim, J | 1 |
| Oh, JY | 1 |
| Jang, J | 1 |
| Hong, S | 1 |
| Song, MA | 1 |
| Shin, HS | 1 |
| Jung, YR | 1 |
| Park, HJ | 1 |
| Riahi, G | 2 |
| Samadi, P | 3 |
| Parent, M | 3 |
| Zhang, L | 1 |
| Balan, G | 1 |
| Barreiro, G | 1 |
| Boscoe, BP | 1 |
| Chenard, LK | 1 |
| Cianfrogna, J | 1 |
| Claffey, MM | 1 |
| Chen, L | 2 |
| Coffman, KJ | 1 |
| Drozda, SE | 1 |
| Dunetz, JR | 1 |
| Fonseca, KR | 1 |
| Galatsis, P | 1 |
| Grimwood, S | 1 |
| Lazzaro, JT | 1 |
| Mancuso, JY | 1 |
| Miller, EL | 1 |
| Reese, MR | 1 |
| Rogers, BN | 1 |
| Sakurada, I | 1 |
| Skaddan, M | 1 |
| Smith, DL | 1 |
| Stepan, AF | 1 |
| Trapa, P | 1 |
| Tuttle, JB | 1 |
| Verhoest, PR | 1 |
| Walker, DP | 1 |
| Wright, AS | 1 |
| Zaleska, MM | 1 |
| Zasadny, K | 1 |
| Shaffer, CL | 1 |
| Morin, N | 4 |
| Jourdain, VA | 2 |
| Ko, WK | 1 |
| Johnston, TM | 1 |
| Fox, SH | 8 |
| Ando, K | 1 |
| Inoue, T | 1 |
| Itoh, T | 1 |
| Urs, NM | 1 |
| Bido, S | 1 |
| Peterson, SM | 1 |
| Daigle, TL | 1 |
| Bass, CE | 1 |
| Gainetdinov, RR | 1 |
| Caron, MG | 1 |
| Zhang, D | 1 |
| McGregor, M | 1 |
| Bordia, T | 1 |
| Perez, XA | 1 |
| McIntosh, JM | 1 |
| Decker, MW | 1 |
| Quik, M | 5 |
| Rajput, A | 1 |
| Rajput, AH | 1 |
| Bagga, P | 1 |
| Crescenzi, R | 1 |
| Krishnamoorthy, G | 1 |
| Verma, G | 1 |
| Nanga, RP | 1 |
| Reddy, D | 1 |
| Greenberg, J | 1 |
| Detre, JA | 1 |
| Hariharan, H | 1 |
| Reddy, R | 1 |
| Muñoz, A | 1 |
| Gardoni, F | 1 |
| Marcello, E | 1 |
| Qin, C | 1 |
| Carlsson, T | 1 |
| Kirik, D | 1 |
| Di Luca, M | 1 |
| Björklund, A | 1 |
| Carta, M | 1 |
| Visanji, NP | 2 |
| Johnston, T | 1 |
| Reyes, G | 1 |
| Millan, MJ | 1 |
| Brotchie, JM | 8 |
| Graham, J | 1 |
| Bédard, PJ | 19 |
| Bartoszyk, GD | 1 |
| Yabe, H | 1 |
| Choudhury, ME | 1 |
| Kubo, M | 1 |
| Nishikawa, N | 1 |
| Nagai, M | 1 |
| Nomoto, M | 1 |
| Astradsson, A | 1 |
| Jenkins, BG | 1 |
| Choi, JK | 1 |
| Hallett, PJ | 3 |
| Levesque, MA | 1 |
| McDowell, JS | 1 |
| Brownell, AL | 1 |
| Spealman, RD | 1 |
| Isacson, O | 1 |
| Kim, ST | 1 |
| Son, HJ | 1 |
| Choi, JH | 1 |
| Ji, IJ | 1 |
| Hwang, O | 1 |
| Silverdale, MA | 2 |
| Kobylecki, C | 1 |
| Dunah, AW | 1 |
| Ravenscroft, P | 2 |
| Saiki, H | 1 |
| Hayashi, T | 1 |
| Takahashi, R | 1 |
| Takahashi, J | 1 |
| Rylander, D | 1 |
| O'Sullivan, SS | 1 |
| Dovero, S | 3 |
| Lees, AJ | 1 |
| Descarries, L | 1 |
| Cenci, MA | 1 |
| Lieu, CA | 1 |
| Deogaonkar, M | 1 |
| Bakay, RA | 2 |
| Subramanian, T | 1 |
| Conte-Perales, L | 1 |
| Rico, AJ | 1 |
| Barroso-Chinea, P | 2 |
| Gómez-Bautista, V | 1 |
| Roda, E | 1 |
| Luquin, N | 1 |
| Sierra, S | 1 |
| Lanciego, JL | 2 |
| Hansard, MJ | 3 |
| Smith, LA | 10 |
| Jackson, MJ | 14 |
| Cheetham, SC | 1 |
| Jenner, P | 21 |
| Tel, BC | 1 |
| Braceras, R | 1 |
| Bonhomme, C | 1 |
| Chezaubernard, C | 1 |
| Del Signore, S | 1 |
| Klintenberg, R | 1 |
| Svenningsson, P | 1 |
| Gunne, L | 1 |
| Andrén, PE | 1 |
| Oh, JD | 3 |
| Bibbiani, F | 3 |
| Chase, TN | 6 |
| Henry, B | 3 |
| Hill, M | 1 |
| Crossman, A | 1 |
| Brotchie, J | 1 |
| Kuoppamäki, M | 4 |
| Al-Barghouthy, G | 4 |
| Smith, L | 3 |
| Zeng, BY | 2 |
| Quinn, N | 1 |
| Maratos, EC | 2 |
| Pearce, RK | 7 |
| Cannizzaro, C | 1 |
| Maratos, E | 1 |
| Ferry, S | 1 |
| Mach, U | 1 |
| Stark, H | 1 |
| Leriche, L | 1 |
| Boraud, T | 2 |
| Gross, C | 1 |
| Sokoloff, P | 1 |
| Chassain, C | 1 |
| Eschalier, A | 1 |
| Durif, F | 1 |
| Iravani, MM | 3 |
| Crossman, AR | 6 |
| Schneider, JS | 3 |
| Gonczi, H | 1 |
| Decamp, E | 1 |
| Petzer, JP | 1 |
| Castagnoli, N | 1 |
| Chen, JF | 1 |
| Schwarzschild, MA | 1 |
| Bélanger, N | 2 |
| Hadj Tahar, A | 4 |
| Nevet, A | 1 |
| Morris, G | 1 |
| Saban, G | 1 |
| Fainstein, N | 1 |
| Bergman, H | 1 |
| Linazasoro, G | 1 |
| Olanow, W | 2 |
| Aubert, I | 2 |
| Guigoni, C | 2 |
| Håkansson, K | 1 |
| Barthe, N | 1 |
| Bioulac, BH | 2 |
| Gross, CE | 3 |
| Fisone, G | 1 |
| Bloch, B | 2 |
| Hagan, JJ | 1 |
| Hurley, MJ | 1 |
| Costa, S | 1 |
| Al-Bargouthy, G | 1 |
| Obeso, JA | 2 |
| Ohashi, S | 1 |
| Mori, A | 1 |
| Kurihara, N | 1 |
| Mitsumoto, Y | 1 |
| Nakai, M | 1 |
| Dridi, M | 1 |
| Calon, F | 4 |
| Meltzer, LT | 1 |
| Lang, AE | 2 |
| Tayarani-Binazir, K | 2 |
| Chu, WB | 1 |
| Gomez-Ramirez, J | 1 |
| Johnston, TH | 1 |
| Pires, D | 1 |
| Voon, V | 1 |
| Smith, CP | 1 |
| Collins, MA | 1 |
| Avila, I | 1 |
| Cox, H | 2 |
| Togasaki, DM | 1 |
| Langston, JW | 3 |
| Di Monte, DA | 2 |
| Cao, X | 1 |
| Liang, L | 1 |
| Hadcock, JR | 1 |
| Iredale, PA | 1 |
| Griffith, DA | 1 |
| Menniti, FS | 1 |
| Factor, S | 1 |
| Greenamyre, JT | 1 |
| Papa, SM | 3 |
| Zubair, M | 1 |
| Stockwell, KA | 1 |
| Parameswaran, N | 1 |
| O'Leary, K | 1 |
| Di Monte, D | 2 |
| Rodríguez-Oroz, MC | 1 |
| Blesa, FJ | 1 |
| Alvarez-Erviti, L | 1 |
| Guridi, J | 1 |
| Smith, Y | 1 |
| Nicholas, AP | 1 |
| Lubin, FD | 1 |
| Vattem, P | 1 |
| Zhou, S | 1 |
| Sweatt, JD | 1 |
| Standaert, DG | 1 |
| Blair, RD | 1 |
| Goulet, M | 5 |
| Blanchet, PJ | 9 |
| Martel, JC | 1 |
| Piercey, MF | 1 |
| Fornai, F | 1 |
| Alessandri, MG | 1 |
| Saginario, A | 1 |
| Vaglini, F | 1 |
| Corsini, GU | 2 |
| Boucher, R | 3 |
| Gomez-Mancilla, B | 4 |
| Blanchette, P | 1 |
| Gagnon, C | 1 |
| Falardeau, P | 2 |
| DiPaolo, T | 1 |
| Shevko, GN | 1 |
| Lukhanina, EP | 1 |
| Kolomiets, BP | 1 |
| Cardoso, F | 1 |
| Jankovic, J | 1 |
| Smith, RD | 1 |
| Zhang, Z | 1 |
| Kurlan, R | 1 |
| McDermott, M | 1 |
| Gash, DM | 1 |
| Pope-Coleman, A | 1 |
| Marsden, CD | 3 |
| Grondin, R | 5 |
| Arai, N | 1 |
| Isaji, M | 1 |
| Kojima, M | 1 |
| Mizuta, E | 1 |
| Kuno, S | 1 |
| Lopez, W | 1 |
| Jeste, DV | 1 |
| Britton, DR | 2 |
| Shiosaki, K | 2 |
| Banerji, T | 1 |
| Konitsiotis, S | 2 |
| Willis, GL | 1 |
| Armstrong, SM | 1 |
| Desimone, R | 1 |
| Fiorani, M | 1 |
| Oldfield, EH | 1 |
| Madras, BK | 1 |
| Kanda, T | 1 |
| Nakamura, J | 1 |
| Kase, H | 1 |
| Kuwana, Y | 1 |
| Verhagen, L | 1 |
| Lamers, E | 1 |
| Mohanakumar, KP | 1 |
| Muralikrishnan, D | 1 |
| Thomas, B | 1 |
| McCormack, A | 1 |
| Petzinger, G | 1 |
| Janson, AM | 1 |
| Langston, WJ | 1 |
| Treseder, SA | 1 |
| Aziz, TZ | 1 |
| Davies, L | 1 |
| Stein, J | 1 |
| France, S | 1 |
| Doucet, JP | 1 |
| Robertson, GS | 1 |
| Nestler, E | 1 |
| Ekesbo, A | 1 |
| Bangassoro, E | 1 |
| Svensson, KA | 1 |
| Tedroff, J | 1 |
| Bioulac, B | 1 |
| Petzinger, GM | 1 |
| Ivashina, E | 1 |
| Jakowec, MW | 1 |
| Jakubiak, M | 1 |
| Hill, MP | 1 |
| Peggs, D | 1 |
| Page, RD | 1 |
| Chen, S | 1 |
| Yoshida, M | 1 |
| Boyce, S | 4 |
| Rupniak, NM | 4 |
| Steventon, MJ | 2 |
| Iversen, SD | 4 |
| Taylor, JR | 1 |
| Elsworth, JD | 1 |
| Roth, RH | 1 |
| Collier, TJ | 1 |
| Sladek, JR | 1 |
| Redmond, DE | 1 |
| Watts, RL | 1 |
| Herring, CJ | 1 |
| Sweeney, KM | 1 |
| Colbassani, HJ | 1 |
| Mandir, A | 1 |
| Byrd, LD | 1 |
| Iuvone, PM | 1 |
| Steventon, M | 1 |
| Tye, SJ | 1 |
| Naruse, T | 1 |
| Miyaji, M | 1 |
| Clarke, CE | 2 |
| Sambrook, MA | 2 |
| Stahl, SM | 1 |
| Pintus, S | 1 |
| Chiueh, CC | 1 |
| Weiss, JF | 1 |
| Kopin, IJ | 1 |
| Bouchard, S | 1 |
| Lieberman, AN | 1 |
| Mitchell, IJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Role of Sleep Homeostasis in the Development of the L-Dopa Induced Dyskinesias in Patients With Parkinson's Disease[NCT02200887] | 48 participants (Actual) | Observational | 2013-09-30 | Completed | |||
| A Phase II, Randomized, Open-label, Double-blind, Two-center Study to Evaluate the Tolerability, Safety and Dose-finding of Oil Cannabis Preparation for Pain in Parkinson's Disease[NCT03639064] | Phase 2 | 15 participants (Anticipated) | Interventional | 2020-12-01 | Recruiting | ||
| Common Noradrenergic Mechanisms in Parkinson´s Disease and L-DOPA Induced Dyskinesia and Healthy Age Matched Controls; [11C]Yohimbine and [11C]MeNER PET[NCT02578849] | 45 participants (Anticipated) | Observational | 2012-01-31 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
13 reviews available for 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and Dyskinesia, Drug-Induced
| Article | Year |
|---|---|
The MPTP-lesioned marmoset model of Parkinson's disease: proposed efficacy thresholds that may potentially predict successful clinical trial results.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Calli | 2020 |
Symptomatic Models of Parkinson's Disease and L-DOPA-Induced Dyskinesia in Non-human Primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine Agents; Dysk | 2015 |
The MPTP-treated primate as a model of motor complications in PD: primate model of motor complications.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine Agonists; Dr | 2003 |
Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Catechols; Disease Mode | 2004 |
Recent failures of new potential symptomatic treatments for Parkinson's disease: causes and solutions.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenergic Agents; Animals; Antiparkinson Agents; Dise | 2004 |
Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: keys to success and roads to failure.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Basal Ganglia; Clinical | 2006 |
Parkinson's disease in 1984: an update.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Animals; Dementia; Drug Therapy, Combination; Dy | 1984 |
Movement disorders.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Alcoholism; Amphetamines; Cocaine; Dyskinesia, Drug-In | 1993 |
DOPA-induced "peak dose" dyskinesia: clues implicating D2 receptor-mediated mechanisms using dopaminergic agonists in MPTP monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dihydroxyphenylalanine; Dopamine Agonists; Dy | 1995 |
Movement disorders and substance abuse.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Alcoholism; Central Nervous System Stimulants; Drug In | 1997 |
Reliability and validity of a new global dyskinesia rating scale in the MPTP-lesioned non-human primate.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dopamine Agents; Drug Administration Schedule | 2001 |
The use of thalamotomy in the treatment of levodopa-induced dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain Mapping; Dyskinesia, Drug-Induced; Fema | 1992 |
The neuronal mechanism underlying parkinsonism and dyskinesia: differential roles of the putamen and caudate nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia; Cats; Caudate Nucleus; Dyskine | 1991 |
115 other studies available for 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and Dyskinesia, Drug-Induced
| Article | Year |
|---|---|
Additive effects of mGluR
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Bridg | 2021 |
Prevention of L-Dopa-Induced Dyskinesias by MPEP Blockade of Metabotropic Glutamate Receptor 5 Is Associated with Reduced Inflammation in the Brain of Parkinsonian Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Dyskinesia, Drug-Induced; Humans; Infl | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
Intraventricular dopamine infusion alleviates motor symptoms in a primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Disease Models, Animal; | 2020 |
Antiparkinsonian Effects of a Metabotropic Glutamate Receptor 4 Agonist in MPTP-Treated Marmosets.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Disabled Persons; Disease Models, | 2020 |
Monoamine oxidase A inhibition with moclobemide enhances the anti-parkinsonian effect of L-DOPA in the MPTP-lesioned marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Basal Ganglia; Behavior | 2020 |
Effects of a combination treatment of KD5040 and
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Cyclic AMP Response Element-Binding Pr | 2017 |
Nefazodone reduces dyskinesia, but not psychosis-like behaviours, in the parkinsonian marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Calli | 2018 |
Basal ganglia serotonin 1B receptors in parkinsonian monkeys with L-DOPA-induced dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Basal Ganglia; Behavior, Ani | 2013 |
Discovery and preclinical characterization of 1-methyl-3-(4-methylpyridin-3-yl)-6-(pyridin-2-ylmethoxy)-1H-pyrazolo-[3,4-b]pyrazine (PF470): a highly potent, selective, and efficacious metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulat
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Allosteric Regulation; Animals; | 2014 |
Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Basal Ganglia; Corpus S | 2014 |
Effects of L-tryptophan on L-DOPA-induced dyskinesia in the L-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Corpus Striatum; Dopami | 2014 |
Effect of a chronic treatment with an mGlu5 receptor antagonist on brain serotonin markers in parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Benserazide; | 2015 |
L-DOPA-induced behavioral sensitization of motor activity in the MPTP-treated common marmoset as a Parkinson's disease model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Callithrix; Dyskinesia, | 2014 |
Targeting β-arrestin2 in the treatment of L-DOPA-induced dyskinesia in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Arrestins; Behavior, Animal; beta-Arrestins; | 2015 |
Changes in glutamate receptors in dyskinetic parkinsonian monkeys after unilateral subthalamotomy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Basal Ganglia; Disease | 2015 |
α7 nicotinic receptor agonists reduce levodopa-induced dyskinesias with severe nigrostriatal damage.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha7 Nicotinic Acetylcholine Receptor; Animals; Anti | 2015 |
Brain α7 nicotinic acetylcholine receptors in MPTP-lesioned monkeys and parkinsonian patients.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Aged, 80 and over; alpha7 Nicotinic Acetylcholin | 2016 |
Mapping the alterations in glutamate with GluCEST MRI in a mouse model of dopamine deficiency.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Astrocytes; Brain Chemistry; Dopamine; Dopami | 2016 |
Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antip | 2008 |
Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Benzopyrans; Callithrix | 2009 |
Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Disea | 2009 |
Zonisamide increases dopamine turnover in the striatum of mice and common marmosets treated with MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Anticonvulsan | 2009 |
The blood-brain barrier is intact after levodopa-induced dyskinesias in parkinsonian primates--evidence from in vivo neuroimaging studies.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Blood-Brain Barrier; Br | 2009 |
Vertical grid test and modified horizontal grid test are sensitive methods for evaluating motor dysfunctions in the MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biomechanical Phenomena; Chromatography, High | 2010 |
Synaptic recruitment of AMPA glutamate receptor subunits in levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Cell Membrane; Dyskines | 2010 |
Objective and quantitative evaluation of motor function in a monkey model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Brain Mapping; Carbon Radioisotopes; C | 2010 |
Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Animals; Brain-Derived Neurotrophic Factor; Corp | 2010 |
Dyskinesias do not develop after chronic intermittent levodopa therapy in clinically hemiparkinsonian rhesus monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Carot | 2011 |
Brain 5-HT(2A) receptors in MPTP monkeys and levodopa-induced dyskinesias.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Bioge | 2011 |
Pallidothalamic-projecting neurons in Macaca fascicularis co-express GABAergic and glutamatergic markers as seen in control, MPTP-treated and dyskinetic monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Colorimetry; DNA Primers; Dopamine; Dyskinesi | 2011 |
Dopamine reuptake inhibition and failure to evoke dyskinesia in MPTP-treated primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Dopamine Uptake Inhibitors; Dose- | 2002 |
Repeated administration of piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: a behavioural and biochemical investigation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Arousal; Callithrix; Ca | 2002 |
Naloxone reduces levodopa-induced dyskinesias and apomorphine-induced rotations in primate models of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benserazide; Callithrix; Dopamine; Dopamine A | 2002 |
Quetiapine attenuates levodopa-induced motor complications in rodent and primate parkinsonian models.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antipsychotic Agents; Behavior, Animal; Diben | 2002 |
Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Benserazide; Callithrix | 2002 |
Beginning-of-dose and rebound worsening in MPTP-treated common marmosets treated with levodopa.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Disease Models, Animal; Dose-Resp | 2002 |
Both short- and long-acting D-1/D-2 dopamine agonists induce less dyskinesia than L-DOPA in the MPTP-lesioned common marmoset (Callithrix jacchus).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Apomorphine; Behavior, | 2003 |
Effect of pulsatile administration of levodopa on dyskinesia induction in drug-naïve MPTP-treated common marmosets: effect of dose, frequency of administration, and brain exposure.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Callithrix; Carbidopa; | 2003 |
Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acrylamides; Animals; Antiparkinson Agents; Dopamine A | 2003 |
Antidyskinetic effect of magnesium sulfate in MPTP-lesioned monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Disea | 2003 |
3,4-methylenedioxymethamphetamine (ecstasy) inhibits dyskinesia expression and normalizes motor activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Calli | 2003 |
Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Aged, 80 and over; Animals; Antiparkinson Agents | 2003 |
Development of levodopa-induced dyskinesias in parkinsonian monkeys may depend upon rate of symptom onset and/or duration of symptoms.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Appetite; Behavior, Animal; Blinking; Dopamin | 2003 |
Opioid antagonists increase the dyskinetic response to dopaminergic agents in parkinsonian monkeys: interaction between dopamine and opioid systems.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzazepines; Dopamine; Dopamine Agents; Dopa | 2003 |
A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenosine A2 Receptor Antagonists; Animals; Antiparkin | 2003 |
Chronic treatment with small doses of cabergoline prevents dopa-induced dyskinesias in parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Caber | 2003 |
Discharge rate of substantia nigra pars reticulata neurons is reduced in non-parkinsonian monkeys with apomorphine-induced orofacial dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Dopamine Agents; Dopamine Agonis | 2004 |
Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Callithrix; Carbidopa; | 2005 |
Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzaze | 2005 |
Effect of 5-HT1B/D receptor agonist and antagonist administration on motor function in haloperidol and MPTP-treated common marmosets.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Dose-Response Relationship, Drug; | 2004 |
Immunoautoradiographic analysis of NMDA receptor subunits and associated postsynaptic density proteins in the brain of dyskinetic MPTP-treated common marmosets.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Blotting, Western; Brai | 2005 |
Unilateral pallidotomy in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets exhibiting levodopa-induced dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Dopamine Agents; Dyskinesia, Drug | 2005 |
DHEA improves symptomatic treatment of moderately and severely impaired MPTP monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Dehydroepiandrosterone; | 2006 |
Age-related severity of dopaminergic neurodegeneration to MPTP neurotoxicity causes motor dysfunction in C57BL/6 mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Age Factors; Aging; Animals; Brain; Cell Death; Corpus | 2006 |
Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; | 2006 |
Enhanced preproenkephalin-B-derived opioid transmission in striatum and subthalamic nucleus converges upon globus pallidus internalis in L-3,4-dihydroxyphenylalanine-induced dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Antiparkinson Agents; C | 2007 |
In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with\\ increased motor disability.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Benzo | 2006 |
Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Apomorphine | 2006 |
Decreased expression of l-dopa-induced dyskinesia by switching to ropinirole in MPTP-treated common marmosets.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Dopamine Agents; Dopamine Agonist | 2007 |
Tamoxifen effect on L-DOPA induced response complications in parkinsonian rats and primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Disease Models, Animal; | 2007 |
The selective kappa-opioid receptor agonist U50,488 reduces L-dopa-induced dyskinesias but worsens parkinsonism in MPTP-treated primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl | 2007 |
Blockade of cannabinoid type 1 receptors augments the antiparkinsonian action of levodopa without affecting dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated rhesus monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Azetidines; Behavior, A | 2007 |
The administration of entacapone prevents L-dopa-induced dyskinesia when added to dopamine agonist therapy in MPTP-treated primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Callithrix; Catechols; | 2007 |
Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Circadian Rhythm; Dyskinesia, Drug-Induced; L | 2007 |
Lesion of the centromedian thalamic nucleus in MPTP-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dyskinesia, Drug-Induced; Functional Laterali | 2008 |
Striatal histone modifications in models of levodopa-induced dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acetylation; Animals; Chromatin; Chromosome Aberration | 2008 |
Levodopa or D2 agonist induced dyskinesia in MPTP monkeys: correlation with changes in dopamine and GABAA receptors in the striatopallidal complex.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aminoquinolines; Animals; Autoradiography; Corpus Stri | 1995 |
beta,beta'-Iminodipropionitrile-induced persistent dyskinetic syndrome in mice is transiently modified by MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Biogenic Monoamines; Cerebr | 1993 |
Excitotoxic lateral pallidotomy does not relieve L-dopa-induced dyskinesia in MPTP parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dyskinesia, Drug-Induced; Female; Globus Pall | 1994 |
Role of selective D1 and D2 agonists in inducing dyskinesia in drug-naive MPTP monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Brain Mapping; Carbidop | 1993 |
Participation of nucleus entopeduncularis in motor instrumental reflex and entopeduncular influences on motor thalamic nuclei in normal and MPTP-treated cats.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cats; Corpus Striatum; Dopamine; Dopamine Age | 1993 |
Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Atropine; Baclofen; Clonidine; Dopamine Agent | 1993 |
Developing a stable bilateral model of parkinsonism in rhesus monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Carbidopa; Carotid Arteries; Disease Models, | 1993 |
Cognitive deficits precede motor deficits in a slowly progressing model of parkinsonism in the monkey.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cognition Disorders; Discrimination Learning; | 1995 |
Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Chore | 1996 |
Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Animals; Antiparkinson Agents; C | 1995 |
Dyskinesia and wearing-off following dopamine D1 agonist treatment in drug-naive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzazepines; Brain; Dopamine Agents; Dopamin | 1996 |
Dyskinesias and tolerance induced by chronic treatment with a D1 agonist administered in pulsatile or continuous mode do not correlate with changes of putaminal D1 receptors in drug-naive MPTP monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzazepines; Catecholamines; Dopamine Agonis | 1996 |
Combined effects of cabergoline and L-dopa on parkinsonism in MPTP-treated cynomolgus monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Caber | 1996 |
Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929: an acute study in parkinsonian levodopa-primed monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Dopamine Agents; Dopami | 1997 |
De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Bromocriptine; Callithr | 1998 |
Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dopamine Ag | 1998 |
Actions of the D1 agonists A-77636 and A-86929 on locomotion and dyskinesia in MPTP-treated L-dopa-primed common marmosets.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adamantane; Animals; Benzopyrans; Callithrix; Disease | 1999 |
A therapeutic role for melatonin antagonism in experimental models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biological Availability; Body Weight; Circadi | 1999 |
Internal globus pallidus discharge is nearly suppressed during levodopa-induced dyskinesias.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Carbidopa; Drug Combina | 1999 |
D(1) dopamine receptor agonists are more effective in alleviating advanced than mild parkinsonism in 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Benzazepines; Dopamine Agen | 2000 |
Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Animals; Callithrix; Carbidopa; | 2000 |
AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzodiazepines; Dioxoles; Disease Models, An | 2000 |
125I-CGP 64213 binding to GABA(B) receptors in the brain of monkeys: effect of MPTP and dopaminomimetic treatments.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Autoradiography; Basal | 2000 |
Neuroprotection by sodium salicylate against 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-induced neurotoxicity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Ani | 2000 |
Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Brain Mapping; Corpus S | 2000 |
Endogenous dopaminergic tone and dopamine agonist action.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adamantane; alpha-Methyltyrosine; Animals; Antiparkins | 2000 |
The role of descending basal ganglia connections to the brain stem in parkinsonian akinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia; Brain Mapping; Brain Stem; Dom | 1998 |
Dopamine-receptor stimulation: biobehavioral and biochemical consequences.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Basal Ganglia; Disease | 2000 |
Effects of acute and repeated treatment with a novel dopamine D2 receptor ligand on L-DOPA-induced dyskinesias in MPTP monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Benserazide; Dopamine A | 2001 |
Dopamine agonist-induced dyskinesias are correlated to both firing pattern and frequency alterations of pallidal neurones in the MPTP-treated monkey.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzaze | 2001 |
Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naïve MPTP-lesioned common marmosets (Callithrix jacchus).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Callithrix; Dose-Respon | 2001 |
Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: evidence from the effects of the alpha(2) adrenoceptor antagonist idazoxan.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenergic alpha-Antagonists; Animals; Antiparkinson A | 2001 |
Striatal AMPA receptor binding is unaltered in the MPTP-lesioned macaque model of Parkinson's disease and dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Alanine; Animals; Apomorphine; Autoradiography; Bindin | 2002 |
Effect of estrogen and progesterone on L-dopa induced dyskinesia in MPTP-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Drug Therapy, Combination; Dyskinesia, Drug-I | 1992 |
[Dopa-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated hemiparkinsonian monkeys].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amphetamines; Animals; Apomorphine; Benserazide; Carbo | 1992 |
Differential effects of D1 and D2 agonists in MPTP-treated primates: functional implications for Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzaze | 1990 |
Improvements in MPTP-induced object retrieval deficits and behavioral deficits after fetal nigral grafting in monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain Tissue Transplantation; Caudate Nucleus | 1990 |
Preliminary report on adrenal medullary grafting and cografting with sural nerve in the treatment of hemiparkinson monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenal Medulla; Animals; Apomorphine; Behavior, Anima | 1990 |
CCK-8S inhibits L-dopa-induced dyskinesias in parkinsonian squirrel monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dyskinesia, Drug-Indu | 1990 |
Characterisation of dyskinesias induced by L-dopa in MPTP-treated squirrel monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Chorea; Dose-Response Relationship, Drug; Dys | 1990 |
Effect of D1 receptor stimulation in normal and MPTP monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzaze | 1989 |
Levodopa-induced dyskinesias in parkinsonian monkeys: relationship to extent of nigrostriatal damage.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Dopamine; Dopamine Agents; D | 1989 |
NB-355: a novel prodrug for L-DOPA with reduced risk for peak-dose dyskinesias in MPTP-treated squirrel monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dose-Response Relationship, Drug; Dyskinesia, | 1989 |
Behavioural effects of (+)-4-propyl-9-hydroxynaphthoxazine in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Dopamine; Dopamine Agents; | 1988 |
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in mice is enhanced by pretreatment with diethyldithiocarbamate.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Biogenic Amin | 1985 |
Behavioral and biochemical effect of chronic treatment with D-1 and/or D-2 dopamine agonists in MPTP monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzaze | 1988 |
Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Benserazide; Carbidopa; Drug Ther | 1986 |
Levodopa-induced dyskinesia and response fluctuations in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dyskinesia, Drug-Indu | 1987 |